Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/69—Boron compounds
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K39/00—Medicinal preparations containing antigens or antibodies
  • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
  • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
  • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
  • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P35/00—Antineoplastic agents
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
  • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
  • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
  • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K39/00—Medicinal preparations containing antigens or antibodies
  • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
  • A61K31/19—Carboxylic acids, e.g. valproic acid
  • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
  • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
  • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
  • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/66—Phosphorus compounds
  • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K2317/00—Immunoglobulins specific features
  • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
  • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K2317/00—Immunoglobulins specific features
  • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
  • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Definitions

• the present disclosure relates to the treatment of cancer using a combination therapy comprising an antibody that binds to CD38 and a proteasome inhibitor.
• Multiple myeloma a B-cell tumor of malignant plasma cells within the bone marrow, remains incurable despite advances in novel therapies with proteasome inhibitors (Pis), immunomodulating drugs (DViiD), and stem cell transplant (SCT) therapy.
• Multiple myeloma is characterized by the accumulation of plasma cells in the bone marrow (and other organs) and can result in bone marrow failure, bone destruction, hypercalcemia, and renal failure. It constitutes approximately 1% of all reported neoplasms and approximately 13% of hematologic cancers worldwide. In the Americas, Canada, and Western European countries, approximately 5 to 7 new cases of multiple myeloma are diagnosed per 100,000 people each year.
• the present disclosure provides methods for treating cancer, or preventing cancer recurrence or progression.
• the methods comprise administering to a patient in need thereof i) a proteasome inhibitor of formula (I), or a pharmaceutically acceptable salt thereof, and ii) an anti-CD38 antibody.
• the present disclosure further provides a use of a proteasome inhibitor of formula (I) or a pharmaceutically acceptable salt thereof, wherein the proteasome inhibitor of formula (I) or a pharmaceutically acceptable salt thereof is administered with an anti-CD38 antibody for treating cancer in a patient in need thereof.
• the present disclosure further provides a use of a proteasome inhibitor of formula (I) or a pharmaceutically acceptable salt thereof in the manufacture of at least one medicament for treating cancer, wherein the proteasome inhibitor of formula (I) or a pharmaceutically acceptable salt thereof is administered with an anti-CD38 antibody to a patient in need thereof.
• the present disclosure further provides a therapeutic combination comprising a compound of formula (I), or a pharmaceutically acceptable salt thereof, and an anti-CD38 antibody.
• the present disclosure further provides a pharmaceutical combination comprising a composition comprising a compound of formula (I), or a pharmaceutically acceptable salt thereof, and a composition comprising an anti-CD38 antibody.
• kits comprising an article for sale containing a combination comprising a compound of formula (I), or a pharmaceutically acceptable salt thereof, and an anti-CD38 antibody, each separately packaged with instructions for use to treat cancer.
• the anti-CD38 antibody used in this invention is
• the proteasome inhibitor of formula (I) of this disclosure is a compound of formula (IV)
• the proteasome inhibitor of formula (I) of this disclosure is a compound of formula (Ilia)
• CD38 includes any variants, isoforms and species homologs of human CD38, which are naturally expressed by cells or are expressed on cells transfected with the CD38 gene. Synonyms of CD38, as recognized in the art, include ADP ribosyl cyclase 1, cADPr hydrolase 1, Cd38-rsl, Cyclic ADP-ribose hydrolase 1, 1-19, NIM-R5 antigen.
• Human CD38 comprises an amino acid sequence as set forth in SEQ ID NO: 15.
• anti-CD38 antibody when used herein refers to an antibody which upon binding to CD38 does not induce significant proliferation of peripheral blood mononuclear cells when compared to the proliferation induced by an isotype control antibody or medium alone (as assayed e.g. as described in Ausiello et al., Tissue Antigens 2000, 56, 539-547).
• an anti-CD38 antibody used in the present disclosure is not only a non- agonist, but even an antagonist of CD38.
• An anti-CD38 antibody may bind to an immunoglobulin molecule such as polyclonal antibodies, monoclonal antibodies (mAbs), antibody-like polypeptides, a fragment of an immunoglobulin molecule, or a derivative of either thereof, which has the ability to specifically bind to CD38 under typical physiological conditions for significant periods of time such as at least about 30 minutes, at least about 45 minutes, at least about one hour, at least about two hours, at least about four hours, at least about 8 hours, at least about 12 hours, about 24 hours or more, about 48 hours or more, about 3, 4, 5, 6, 7 or more days, etc., or any other relevant functionally-defined period (such as a time sufficient to induce, promote, enhance, and/or modulate a physiological response associated with antibody binding to CD38).
• an immunoglobulin molecule such as polyclonal antibodies, monoclonal antibodies (mAbs), antibody-like polypeptides, a fragment of an immunoglobulin molecule, or a derivative of either thereof, which has the ability to specifically
• antigen-binding function of an antibody can be performed by fragments of a full-length antibody.
• binding fragments encompassed within the term "anti-CD38 antibody” include (i) a Fab fragment, a monovalent fragment consisting of the V L , VH, C L and C H I domains; (ii) F(ab) 2 and F(ab')2 fragments, bivalent fragments comprising two Fab fragments linked by a disulfide bridge at the hinge region; (iii) a Fd fragment consisting essentially of the V H and C H 1 domains; (iv) a Fv fragment consisting essentially of the VL and V H domains of a single arm of an antibody, (v) a dAb fragment (Ward et al., Nature 1989, 341, 544-546), which consists essentially of a VH domain; (vi) an isolated complementarity determining region (CDR), and (vii) a combination of two or more isolated CDR
• the two domains of the Fv fragment, V L and V H are coded for by separate genes, they can be joined, using recombinant methods, by a synthetic linker that enables them to be made as a single protein chain in which the V L and V H regions pair to form monovalent molecules (known as single chain antibodies or single chain Fv (scFv) (see for instance Bird et al., Science 1988, 242, 423-426 and Huston et al., Proc. Natl. Acad. Sci. USA 1988, 85, 5879- 5883).
• single chain antibodies are encompassed within the term "anti-CD38 antibody” unless otherwise noted or clearly indicated by context.
• single chain antibodies such as diabodies
• anti-CD38 antibody see for instance Proc. Natl. Acad. Sci. USA 1993, 90(14), 6444-6448 for a description of diabodies.
• fragments are generally included within the meaning of antibody, they collectively and each independently are unique features of the present disclosure, exhibiting different biological properties and utility. These and other useful antibody fragments in the context of the present disclosure are discussed further herein.
• daratumumab refers to a full-length human monoclonal anti-CD38 antibody described in US Patent No. 7,829,673.
• Daratumumab is characterized in US Patent No. 7,829,673 as antibody -005.
• Daratumumab may also be referred to for example as "HuMax®-CD38.”
• the method to generate, isolate, and obtain daratumumab and its amino acid and encoding nucleotide sequences are described in US Patent No. 7,829,673, which is incorporated by reference specifically and in its entirety.
• Daratumumab comprises a heavy chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 9 or encoded by the nucleotide sequence set forth in SEQ ID NO: 8.
• Daratumumab comprises a light chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 4 or encoded by the nucleotide sequence set forth in SEQ ID NO: 3.
• Proteasome inhibitors are agents that block the action of proteasomes, cellular complexes that break down proteins such as the p53 protein. Proteasome inhibitors are being studied in the treatment of cancer, especially multiple myeloma. Examples of proteasome inhibitors are: bortezomib, carfilzomib, disulfiram, epigallocatechin-3-gallate, salinosporamid A, ONX0912, CEP- 18770, and Epoxomicin.
• oral forms include, but are not limited to, tablets, pills, capsules, powders, granules, solutions or suspensions, and drops. Such forms may be swallowed whole or may be in chewable form.
• infusion refers to the administration of a composition through a needle or catheter. Infusion may mean that a drug is administered intravenously, but the term also may refer to situations where drugs are provided through other non-oral routes, such as
• intramuscular injections and epidural routes into the membranes surrounding the spinal cord.
• boronate ester and “boronic ester” are used interchangeably and refer to a chemical compound containing a -B(Z')(Z 2 ) moiety, wherein Z 1 and Z 2 together form a cyclic boronic ester having 2-20 carbon atoms, and optionally one or more heteroatoms selected from N, S, or O.
• the present disclosure provides methods for treating cancer, or preventing cancer recurrence or progression, in a patient in need of treatment or prevention.
• the methods comprise administering to a patient in need thereof i) a proteasome inhibitor of formula (I), or a pharmaceutically acceptable salt thereof, and ii) an anti-CD38 antibody.
• the present disclosure further provides a therapeutic combination comprising a compound of formula (I), or a pharmaceutically acceptable salt thereof, and an anti-CD38 antibody.
• the present disclosure further provides a pharmaceutical combination comprising a composition comprising a compound of formula (I), or a pharmaceutically acceptable salt thereof, and a composition comprising an anti-CD38 antibody.
• the present disclosure further provides a kit comprising an article for sale containing a combination comprising a compound of formula (I), or a pharmaceutically acceptable salt thereof, and an anti-CD38 antibody, each separately packaged with instructions for use to treat cancer.
• patient refers to mammalian patients, for example human patients.
• Patients in need of therapeutic treatment and/or prevention also include companion animals such as dogs, rats and horses.
• proteasome inhibitor formula (I) refers to the following formula:
• ring A is selected from
• Z 1 and Z 2 are each independently hydroxyl; or Z 1 and Z 2 together form a cyclic boronic ester having 2-20 carbon atoms, and optionally one or more heteroatoms selected from N, S, or O.
• Z 1 and Z 2 of formula (I) are each independently hydroxyl.
• proteasome inhibitor formula (I) is characterized by formula (la):
• Z and Z 2 are each independently hydroxyl; or Z l and Z 2 together form a cyclic boronic ester having 2-20 carbon atoms, and optionally one or more heteroatoms selected from N, S, or O.
• proteasome inhibitor formula (I) is characterized by formula (II):
• ring A is defined above;
• R l and R 2 are each independently wherein one of carboxylic acids optionally forms a further bond with the boron atom;
• proteasome inhibitor formula (I) is characterized by formula
• proteasome inhibitor formula (I) is a compound of formula my.
• proteasome inhibitor formula (I) is a compound of formula
• the anti-CD38 antibody is a monoclonal antibody.
• the anti-CD38 antibody is a human monoclonal antibody.
• the anti-CD38 antibody is an antagonist of CD38.
• the anti-CD38 antibody is an isolated full-length antibody that binds to human CD38.
• the methods to generate, isolate, and obtain anti-CD38 antibodies are well known in the art, for example, described in US Patent No. 7,829,673, US Patent Publication No. 2010/0092489, US Patent Publication No. 2013/0209355, which are hereby incorporated by reference specifically and in their entirety.
• the anti-CD38 antibody is an antibody comprising a VL region having the amino acid sequence as set forth in SEQ ID NO: 4.
• the anti-CD38 antibody is an antibody comprising a VH region having the amino acid sequence as set forth in SEQ ID NO: 9.
• the anti-CD38 antibody comprises a V L region having the amino acid sequence as set forth in SEQ ID NO: 4 and a VH region having the amino acid sequence as set forth in SEQ ID NO: 9.
• the anti-CD38 antibody is an antibody comprising a VL
• CDRl having the amino acid sequence as set forth in SEQ ID NO: 5.
• the anti-CD38 antibody is an antibody comprising a VL
• CDR2 having the amino acid sequence as set forth in SEQ ID NO: 6.
• the anti-CD38 antibody is an antibody comprising a VL
• CDR3 having the amino acid sequence as set forth in SEQ ID NO: 7.
• the anti-CD38 antibody is an antibody comprising a VH
• CDRl having the amino acid sequence as set forth in SEQ ID NO: 10.
• the anti-CD38 antibody is an antibody comprising a VH
• CDR2 having the amino acid sequence as set forth in SEQ ID NO: 11.
• the anti-CD38 antibody is an antibody comprising a VH
• CDR3 having the amino acid sequence as set forth in SEQ ID NO: 12.
• the anti-CD38 antibody comprises a VL CDRl region comprising the amino acid sequence as set forth in SEQ ID NO: 5, a VL CDR2 region comprising the amino acid sequence as set forth in SEQ ID NO: 6, a VL CDR3 region comprising the amino acid sequence as set forth in SEQ ID NO: 7, a VH CDRl region comprising the amino acid sequence as set forth in SEQ ID NO: 10, a VH CDR2 region comprising the amino acid sequence as set forth in SEQ ID NO: 11 , and a VH CDR3 region comprising the amino acid sequence as set forth in SEQ ID NO: 12.
• the anti-CD38 antibody is daratumumab.
• the anti-CD38 antibody is an antibody comprising a VH region having the amino acid sequence as set forth in SEQ ID NO: 2.
• the anti-CD38 antibody is an antibody comprising a VL region having the amino acid sequence as set forth in SEQ ID NO: 1.
• the anti-CD38 antibody is an antibody comprising a VH region having the amino acid sequence as set forth in SEQ ID NO: 2 and a V L region having the amino acid sequence as set forth in SEQ ID NO: 1.
• the anti-CD38 antibody is an antibody comprising a V H region having the amino acid sequence as set forth in SEQ ID NO: 14.
• the anti-CD38 antibody is an antibody comprising a V L region having the amino acid sequence as set forth in SEQ ID NO: 13.
• the anti-CD38 antibody is an antibody comprising a V H region having the amino acid sequence as set forth in SEQ LD NO: 14 and a VL region having the amino acid sequence as set forth in SEQ LD NO: 13.
• the proteasome inhibitor is a compound of formula (Ilia) and the anti-CD38 antibody comprises a VL region having the amino acid sequence as set forth in SEQ ID NO: 4 and a V H region having the amino acid sequence as set forth in SEQ LD NO: 9.
• a therapeutic combination comprising a proteasome inhibitor and an anti-CD38 antibody is administered with one or more therapeutic agents.
• the other therapeutic agents may also inhibit the proteasome, or may operate by a different mechanism.
• the other therapeutic agents are those that are normally administered to patients with the disease or condition being treated.
• the other therapeutic agent(s) may be administered with the proteasome inhibitor or anti-CD38 antibody in a single dosage form or as a separate dosage form. When administered as a separate dosage form, the other therapeutic agent(s) may be administered prior to, at the same time as, or following administration of proteasome inhibitor or anti-CD38 antibody.
• a therapeutic combination comprising a proteasome inhibitor and an anti-CD38 antibody are administered with one or more anticancer agent(s).
• anticancer agent refers to any agent that is administered to a patient with cancer for purposes of treating the cancer.
• the other therapeutic agent includes DNA damaging chemotherapeutic agents such as topoisomerase I inhibitors (e.g., irinotecan, topotecan, camptothecin and analogs or metabolites thereof, and doxorubicin); topoisomerase II inhibitors (e.g., etoposide, teniposide, and daunorubicin); alkylating agents (e.g., melphalan, chlorambucil, busulfan, thiotepa, ifosfamide, carmustine, lomustine, semustine, streptozocin, decarbazine, methotrexate, mitomycin C, and cyclophosphamide); DNA intercalators (e.g., cisplatin, oxaliplatin, and carboplatin); DNA intercalators and free radical generators such as bleomycin; and nucleoside mimetics (e.g., 5-fluorouraci), 5-fluorouracil
• the other therapeutic agent includes chemotherapeutic agents that disrupt cell replication such as: paclitaxel, docetaxel, and related analogs; vincristine, vinblastin, and related analogs; thalidomide, lenalidomide, and related analogs (e.g., CC-5013 and CC-4047); protein tyrosine kinase inhibitors (e.g., imatinib mesylate and gefitinib); proteasome inhibitors (e.g., bortezomib); NF- ⁇ inhibitors, including inhibitors of ⁇ kinase; antibodies which bind to proteins overexpressed in cancers and thereby downregulate cell replication (e.g., trastuzumab, rituximab, cetuximab, and bevacizumab); and other inhibitors of proteins or enzymes known to be upregulated, over-expressed or activated in cancers, the inhibition of which downregulates cell replication.
• the proteasome inhibitor of formula (I) and anti-CD38 antibody are administered with an immunomodulating agent.
• the immunomodulating agent is thalidomide, lenalidomide or pomalidomide.
• the proteasome inhibitor of formula (I) and anti-CD38 antibody are administered with lenalidomide.
• the proteasome inhibitor of formula (I) and anti-CD38 antibody are administered with an alkylating agent.
• the alkylating agent is melphalan or cyclophosphamide.
• the proteasome inhibitor of formula (I) and anti-CD38 antibody are administered with melphalan.
• the proteasome inhibitor of formula (I) and anti-CD38 antibody are administered with cyclophosphamide.
• the proteasome inhibitor of formula (I) and anti-CD38 antibody are administered with a steroid. In such embodiments, the steroid is
• dexamethasone prednisone, prednisolone, or methylprednisone.
• the proteasome inhibitor of formula (I) and anti-CD38 antibody are administered with dexamethasone.
• the proteasome inhibitor of formula (I) and anti-CD38 antibody are administered with cyclophosphamide and dexamethasone.
• the proteasome inhibitor of formula (Ilia) or (IV) and daratumumab are aclministered with lenalidomide.
• the proteasome inhibitor of formula (Ilia) or (IV) and daratumumab are administered with melphalan.
• the proteasome inhibitor of formula (Ilia) or (IV) and daratumumab are administered with cyclophosphamide.
• the proteasome inhibitor of formula (Ilia) or (IV) and daratumumab are administered with dexamethasone.
• the proteasome inhibitor of formula (Ilia) or (IV) and daratumumab are administered with cyclophosphamide and dexamethasone.
• the method of this disclosure further comprises admimstering to a patient melphalan, lenalidomide, cyclophosphamide, and/or dexamethasone.
• proteasome inhibitors or anti-CD38 antibodies used in the present disclosure may be formulated as a pharmaceutical composition with pharmaceutically acceptable carriers or diluents as well as any other known adjuvants and excipients in accordance with conventional techniques such as those disclosed in Remington: The Science and Practice of Pharmacy,
• compositions used in the present disclosure may also include diluents, fillers, salts, buffers, detergents (e. g., a nonionic detergent, such as Tween- 80), stabilizers (e. g., sugars or protein-free amino acids), preservatives, tissue fixatives, solubilizers, and/or other materials suitable for inclusion in a pharmaceutical composition.
• detergents e. g., a nonionic detergent, such as Tween- 80
• stabilizers e. g., sugars or protein-free amino acids
• preservatives e. g., tissue fixatives, solubilizers, and/or other materials suitable for inclusion in a pharmaceutical composition.
• the compounds used in the present disclosure may be administered via any suitable route, such as an oral, nasal, inhalable, topical (including buccal, transdermal and sublingual), rectal, vaginal and/or parenteral route.
• suitable route such as an oral, nasal, inhalable, topical (including buccal, transdermal and sublingual), rectal, vaginal and/or parenteral route.
• one or more of the proteasome inhibitors used in the present disclosure are administered orally, for example, with an inert diluent or an assimilable edible carrier.
• the active ingredient may be enclosed in a hard or soft shell gelatin capsule, or compressed into tablets.
• Pharmaceutical compositions which are suitable for oral administration include ingestible tablets, buccal tablets, troches, capsules, elixirs, suspensions, syrups, wafers, and the like containing such carriers as are known in the art to be appropriate.
• parenteral aclrninistration' 1 and “administered parenterally” as used herein mean modes of administration other than enteral and topical administration, usually by injection, and include epidermal, intravenous, intramuscular, intraarterial, intrathecal, intracapsular, intraorbital, intracardiac, intradermal, intraperitoneal, intratendinous, transtracheal, subcutaneous, subcuticular, intraarticular, subcapsular, subarachnoid, intraspinal, intracranial, intrathoracic, epidural and intrasternal injection and infusion.
• the proteasome inhibitor is a compound of formula (Ilia), wherein the compound of formula (Ilia) is administered orally.
• the proteasome inhibitor is a compound of formula (Ilia), wherein the compound of formula (Ilia) is enclosed in a capsule and administered orally.
• the anti-CD38 antibody is administered by infusion.
• the anti-CD38 antibody is daratumumab, wherein daratumumab is administered by infusion.
• the anti-CD38 antibody is daratumumab, wherein daratumumab is administered by intravenous infusion.
• the anti-CD38 antibody is daratumumab, wherein daratumumab is administered by continuous infusion over a period of from 2 to 24 hours.
• the anti-CD38 antibody is daratumumab, wherein daratumumab is administered by continuous infusion over a period of from 2 to 12 hours.
• the anti-CD38 antibody is administered by subcutaneous infusion.
• the anti-CD38 antibody is daratumumab, wherein daratumumab is administered by subcutaneous infusion.
• the anti-CD38 antibody is daratumumab, wherein daratumumab is administered with recombinant human hyaluromdase enzyme (rHuPH20).
• the anti-CD38 antibody is daratumumab, wherein daratumumab is administered by subcutaneous infusion over a period of less than 2 hours.
• the proteasome inhibitor is a compound of formula (Ilia) and the anti-CD38 antibody is daratumumab, wherein the compound of formula (Ilia) is enclosed in a capsule and administered orally and
• daratumumab is administered by infusion.
• the methods of this disclosure are useful for treating a patient having, or at risk of developing or experiencing a recurrence of, a proteasome-mediated disorder.
• proteasome-mediated disorder includes any disorder, disease or condition which is caused or characterized by an increase in proteasome expression or activity.
• proteasome-mediated disorder also includes any disorder, disease or condition in which inhibition of proteasome activity is beneficial.
• proteasome-mediated disorders include inflammatory disorders (e.g., rheumatoid arthritis, inflammatory bowel disease, asthma, chronic obstructive pulmonary disease (COPD), osteoarthritis, dermatosis (e.g., atopic dermatitis, psoriasis)), vascular proliferative disorders (e.g., atherosclerosis, restenosis), proliferative ocular disorders (e.g., diabetic retinopathy), benign proliferative disorders (e.g., hemangiomas), autoimmune diseases (e.g., multiple sclerosis, tissue and organ rejection), as well as inflammation associated with infection (e.g., immune responses), antibody-mediated disease, neurodegenerative disorders (e.g.
• inflammatory disorders e.g., rheumatoid arthritis, inflammatory bowel disease, asthma, chronic obstructive pulmonary disease (COPD), osteoarthritis, dermatosis (e.g., atopic dermatiti
• Non-limiting examples of autoimmune diseases and antibody-mediated diseases include systemic lupus erythematosus, lupus nephritis, Sjogren's syndrome, ulcerative colitis, Crohn's disease, type 1 diabetes, myasthenia gravis, idiopathic pulmonary fibrosis, cirrhosis, endomyocardial fibrosis, scleroderma sclerosis, systemic sclerosis, antibody- mediated rejection, antibody-mediated rejection in organ transplantation, antibody-mediated rejection in kidney transplantation, antibody-mediated rejection in lung transplantation, antibody-mediated rejection in heart transplantation, antibody-mediated rejection in liver transplantation, antibody-mediated rejection in pancreas transplantation, or graft versus host disease.
• cancer refers to a cellular disorder characterized by uncontrolled or dis-regulated cell proliferation, decreased cellular differentiation, inappropriate ability to invade surrounding tissue, and/or ability to establish new growth at ectopic sites.
• cancer includes, but is not limited to, solid tumors and hematologic malignancies.
• cancer encompasses diseases of skin, tissues, organs, bone, cartilage, blood, and vessels.
• cancer further encompasses primary and metastatic cancers.
• Non-limiting examples of solid tumors that can be treated with the methods of this disclosure include pancreatic cancer; bladder cancer; colorectal cancer; breast cancer, including metastatic breast cancer; prostate cancer, including androgen-dependent and androgen-independent prostate cancer; renal cancer, including, e.g., metastatic renal cell carcinoma; hepatocellular cancer; lung cancer, including, e.g., non-small cell lung cancer (NSCLC), bronchioloalveolar carcinoma (BAC), and adenocarcinoma of the lung; ovarian cancer, including, e.g., progressive epithelial or primary peritoneal cancer; cervical cancer; gastric cancer; esophageal cancer; head and neck cancer, including, e.g., squamous cell carcinoma of the head and neck; melanoma; neuroendocrine cancer, including metastatic neuroendocrine tumors; brain tumors, including, e.g., glioma, anaplastic oligodendroglioma, adult
• Non-limiting examples of hematologic malignancies that can be treated with the methods of this disclosure include acute myeloid leukemia (AML); chronic myelogenous leukemia (CML), including accelerated CML and CML blast phase (CML-BP); acute lymphoblastic leukemia (ALL); chronic lymphocytic leukemia (CLL); Hodgkin's disease (HD); lymphoma; non-Hodgkin's lymphoma (NHL), including follicular lymphoma and mantle cell lymphoma; B-cell lymphoma; T-cell lymphoma; multiple myeloma (MM);
• MDS myelodysplastic syndromes
• RA refractory anemia
• RARS refractory anemia with ringed siderblasts
• RAEB refractory anemia with excess blasts
• RAEB-T RAEB in transformation
• the methods of this disclosure are useful in treatment of amyloidosis.
• the methods of this disclosure are used to treat a patient having or at risk of developing or experiencing a recurrence (relapse) in a cancer selected from multiple myeloma and mantle cell lymphoma.
• the methods of this disclosure are used to treat a patient with refractory mantle cell lymphoma.
• the methods of this disclosure are used to treat a patient with multiple myeloma.
• the methods of this disclosure are used to treat a patient with refractory multiple myeloma.
• the anti-CD38 antibody is administered to a patient in need thereof in a dose of from about 1-100 mg/kg.
• the anti-CD38 antibody is admimstered to a patient in need thereof in a dose of from about 2-50 mg/kg.
• the anti-CD38 antibody is administered to a patient in need thereof in a dose of from about 2-40 mg/kg.
• the anti-CD38 antibody is administered to a patient in need thereof in a dose of from about 2-30 mg/kg.
• the anti-CD38 antibody is administered to a patient in need thereof in a dose of from about 4-20 mg/kg.
• the anti-CD38 antibody is aa ⁇ ministered to a patient in need thereof in a dose of about 8 mg/kg.
• the anti-CD38 antibody is admimstered to a patient in need thereof in a dose of about 16 mg kg.
• the anti-CD38 antibody is administered daily, once every two days, once every three days, once every four days, once every five days, once every six days, once a week, once every two weeks, or once every four weeks.
• the anti-CD38 antibody is administered once weekly for 2 to 20 weeks, such as for 3 to 12 weeks, such as for 4 to 8 weeks.
• the anti-CD38 antibody is administered once every two weeks, for a period of 1 month or more. [120] In certain embodiments, the anti-CD38 antibody is administered once every four weeks, for a period of 1 month or more.
• the anti-CD38 antibody is administered once weekly for 2-20 weeks, then once every two weeks for a period of 1 month or more, then once every four weeks for a period of 1 month or more.
• the anti-CD38 antibody is administered once weekly for 2-20 weeks, then once every two weeks for a period of 1 month or more.
• the anti-CD38 antibody is administered once weekly for 2-20 weeks, then once every four weeks for a period of 1 month or more.
• the anti-CD38 antibody is administered once every two weeks for a period of 1 month or more, then once every four weeks for a period of 1 month or more.
• the anti-CD38 antibody is administered once weekly for weeks 1-8 weeks, then once every two weeks for weeks 9-24 then once every four weeks for weeks 25 until disease progression.
• the anti-CD38 antibody is administered once weekly for a 28 day cycle repeated twice, then every two week in cycles 3-6 and then every 4 weeks in subsequent cycles until disease progression.
• the anti-CD38 antibody is administered by infusion in a dosage of from 10 to 500 mg/m 2 , such as of from 200 to 400 mg/m 2 .
• Such administration may be repeated, e.g., 1 to 8 times, such as 3 to 5 times.
• the administration may be performed by continuous infusion over a period of from 2 to 24 hours, such as of from 2 to 12 hours.
• the anti-CD38 antibody is administered by slow continuous infusion over a long period, such as more than 24 hours, in order to reduce toxic side effects.
• the anti-CD38 antibody is administered once a week, once every two weeks, or once every four weeks in a dosage of from 250 mg/m 2 to 2000 mg/m 2 , such as for example 300 mg/m 2 , 500 mg/m 2 , 700 mg/m 2 , 1000 mg/m 2 , 1500 mg/m 2 or 2000 mg/m 2 , for up to 8 times, such as from 4 to 6 times.
• the administration may be performed by continuous infusion over a period of from 2 to 24 hours, such as of from 2 to 12 hours.
• Such regimen may be repeated one or more times as necessary, for example, after 6 months or 12 months.
• the dosage may be determined or adjusted by measuring the amount of compound of the present disclosure in the blood upon administration by for instance taking out a biological sample and using anti-idiotypic antibodies which target the antigen binding region of the anti- CD38 antibody.
• the proteasome inhibitor is administered to a patient in need thereof in a dose of from about 0.5-20 mg.
• the proteasome inhibitor is administered to a patient in need thereof in a dose of from about 1-12 mg.
• the proteasome inhibitor is administered to a patient in need thereof in a dose of from about 1.5- 10 mg.
• the proteasome inhibitor is administered to a patient in need thereof in a dose of about 2.3 mg.
• the proteasome inhibitor is administered to a patient in need thereof in a dose of about 3.0 mg.
• the proteasome inhibitor is adrninistered to a patient in need thereof in a dose of about 4.0 mg.
• the proteasome inhibitor is administered to a patient in need thereof in a dose of about 5.3 mg.
• the proteasome inhibitor is administered to a patient in need thereof in a dose of about 5.5 mg.
• the proteasome inhibitor is administered daily, once every two days, once every three days, once every four days, once every five days, once every six days, weekly, once every two weeks, or once every four weeks.
• the proteasome inhibitor is administered once weekly for 2- 20 weeks.
• the proteasome inhibitor is administered on days 1 , 8, 15 of a 28-day schedule.
• the proteasome inhibitor is administered daily, once every two days, once every three days, once every four days, once every five days, once every six days, weekly, once every two weeks, or once every four weeks
• the anti-CD38 antibody is administered daily, once every two days, once every three days, once every four days, once every five days, once every six days, once a week, once every two weeks, or once every four weeks.
• patients are administered with proteasome inhibitor of formula (I) in a dosage of 0.5-20 mg and with anti-CD38 antibody in a dosage of 1-100 mg/kg.
• patients are administered with proteasome inhibitor of formula (I) in a dosage of 1-12 mg and with anti-CD38 antibody in a dosage of 2-50 mg/kg.
• patients are administered with proteasome inhibitor of formula (Ilia) in a dosage of 1-12 mg and with daratumumab in a dosage of 2-50 mg/kg.
• proteasome inhibitor of formula (Ilia) in a dosage of 1-12 mg and with daratumumab in a dosage of 2-50 mg/kg.
• patients are administered with the proteasome inhibitor of (nia) in a dosage of 2.3, 3, 4 or 5.5 mg per scheduled dose and with daratumummab in a dosage of 8 or 16 mg/kg per scheduled dose.
• the proteasome inhibitor of formula (I) and anti-CD38 antibody may be administered simultaneously or sequentially in any order. In certain embodiments, they may be administered separately or in one or more pharmaceutical compositions.
• a given dosing schedule comprises one or more
• ao'ministrations of a proteasome inhibitor/anti-CD38 antibody wherein at least one administration of a proteasome inhibitor/anti-CD38 antibody, such as described herein, may be repeated or cycled on a daily, weekly, biweekly, monthly, bimonthly, annually, semiannually, or any other period.
• a repeated dosing schedule or cycle may be repeated for a fixed period of time determined at the start of the schedule; may be terminated, extended, or otherwise adjusted based on a measure of therapeutic effect, such as a level of reduction in the presence of detectable disease tissue (e.g. a reduction of at least 50%, 60%, 70%, 80%, 90%, 95%, 99%, or 100%); or may be terminated, extended, or otherwise adjusted for any other reason as determined by a medical professional.
• the dosing regimen is an intermittent regimen.
• the intermittent regimen comprises at least one cycle of a treatment period of at least 1 day followed by a rest period of at least 1 day.
• the intermittent dosing regimen can comprise at least one cycle of a treatment period of 2, 3, 4, 5, 6 or 7 days followed by a rest period of at least 1 day.
• the intermittent dosing regimen comprises at least one cycle of a treatment period of 2, 3, 4, 5, 6 or 7 days followed by a rest period of at least 3, 4, or 5 days, at least one cycle of a treatment period of at least 1 day followed by a rest period of 6 days, at least one 7-day cycle of a treatment period of 3 days followed by a rest period of 4 days, at least one 7-day cycle of a treatment period of 5 days followed by a rest period of 2 days, or at least one 7-day cycle of a treatment period of 1 day followed by a rest period of 6 days.
• the intermittent dosing regimen can comprise at least one cycle of a treatment period of 1 day followed by a rest period of 13 days.
• the intermittent dosing regimen can comprise at least one cycle of a treatment period of 1 day followed by a rest period of 20 days. In certain embodiments, the intermittent dosing regimen can comprise at least one cycle of a treatment period of 1 day followed by a rest period of 27 days. In certain embodiments, the intermittent dosing regimen comprises at least one 7-day cycle comprising at least 3 treatment periods on alternate days within the 7 days.
• a patient is administered a combination of (a) a proteasome inhibitor according to a first dosing regimen and (b) an anti-CD38 antibody according to a second dosing regimen.
• the first dosing regimen and the second dosing regimen can be different, or can be the same and are administered simultaneously.
• Each dosing regimen independently comprises repeating cycles of a treatment period followed by a rest period.
• Preferably, at least one dosing regimen has one rest period of more than 0 day.
• one of the first and second dosing regimens is not an intermittent regimen, i.e., a continuous regimen.
• either the first or the second regimen has a rest period of 0 day.
• the first and/or the second dosing regimen independently comprises at least one cycle of a treatment period of at least 1 day followed by a rest period of at least 1 day. In certain embodiments, the first and or the second dosing regimen can independently comprise at least one cycle of a treatment period of 2, 3, 4, 5, 6 or 7 days followed by a rest period of at least 1 day. In certain embodiments, the first and/or the second dosing regimen independently comprises at least one cycle of a treatment period of 2, 3, 4, 5, 6 or 7 days followed by a rest period of at least 3, 4, or 5 days. In certain
• the first and/or the second dosing regimen independently comprises at least one cycle of a treatment period of at least 1 day followed by a rest period of 6 days, at least one cycle of a treatment period of 1 day followed by a rest period of 13 days, at least one cycle of a treatment period of 1 day followed by a rest period of 20 days, or at least one cycle of a treatment period of 1 day followed by a rest period of 27 days.
• the first and/or the second dosing regimen independently comprises at least one 7-day cycle of a treatment period of 3 days followed by a rest period of 4 days, or at least one 7-day cycle of a treatment period of 5 days followed by a rest period of 2 days, or at least one 7-day cycle of a treatment period of 1 day followed by a rest period of 6 days, or at least one 7-day cycle of a treatment period of 1 day followed by a rest period of 6 days.
• the first dosing regimen and the second dosing regimen are the same and are administered simultaneously.

Landscapes

• Health & Medical Sciences (AREA)
• Chemical & Material Sciences (AREA)
• Medicinal Chemistry (AREA)
• Life Sciences & Earth Sciences (AREA)
• General Health & Medical Sciences (AREA)
• Veterinary Medicine (AREA)
• Pharmacology & Pharmacy (AREA)
• Animal Behavior & Ethology (AREA)
• Public Health (AREA)
• Organic Chemistry (AREA)
• Immunology (AREA)
• Epidemiology (AREA)
• Biochemistry (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• General Chemical & Material Sciences (AREA)
• Biophysics (AREA)
• Genetics & Genomics (AREA)
• Molecular Biology (AREA)
• Proteomics, Peptides & Aminoacids (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Engineering & Computer Science (AREA)
• Microbiology (AREA)
• Mycology (AREA)
• Endocrinology (AREA)
• Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Peptides Or Proteins (AREA)
• Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
• Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
• Preparation Of Compounds By Using Micro-Organisms (AREA)

Priority Applications (10)

Applications Claiming Priority (2)

Related Child Applications (2)

Publications (2)

Family

ID=56689146

Family Applications (1)

Country Status (8)

Cited By (13)

Families Citing this family (6)

Family Cites Families (9)

• 2016
  • 2016-02-15 MA MA041555A patent/MA41555A/fr unknown
  • 2016-02-16 CN CN201680010651.6A patent/CN107249635A/zh active Pending
  • 2016-02-16 EP EP16752904.9A patent/EP3258965A4/en not_active Withdrawn
  • 2016-02-16 EA EA201791736A patent/EA201791736A1/ru unknown
  • 2016-02-16 CA CA2976696A patent/CA2976696A1/en active Pending
  • 2016-02-16 JP JP2017542868A patent/JP2018506550A/ja not_active Withdrawn
  • 2016-02-16 WO PCT/US2016/018070 patent/WO2016133903A2/en not_active Ceased
  • 2016-02-16 US US15/551,093 patent/US20180235986A1/en not_active Abandoned
• 2020
  • 2020-12-18 JP JP2020209908A patent/JP2021059564A/ja not_active Withdrawn
• 2021
  • 2021-01-21 US US17/154,498 patent/US20210137955A1/en not_active Abandoned
  • 2021-08-02 US US17/392,158 patent/US20210369748A1/en not_active Abandoned
• 2022
  • 2022-02-25 US US17/680,718 patent/US20220184103A1/en not_active Abandoned
• 2023
  • 2023-03-16 US US18/184,918 patent/US20230201227A1/en not_active Abandoned
  • 2023-07-14 JP JP2023115987A patent/JP2023130496A/ja active Pending

Also Published As

Similar Documents

Legal Events